Researchers identify gene variant associated with cellular aging

Medical Xpress | March 20, 2019

It is well known that psychiatric stress is associated with accelerated aging. Now, a new study shows that a gene mutation interacts with multiple types of psychiatric stress including post-traumatic stress disorder (PTSD), pain and sleep disturbances in association with cellular aging. The klotho gene, which is named for the Greek Goddess Clotho who "spins the thread of life," has been connected with longevity and a variety of age-related conditions and diseases. This is the first time it has been shown to be a marker for accelerated cellular aging in humans. The study involved 309 U.S. military veterans, of which a large percentage experienced PTSD, who had been deployed to the wars in Iraq and/or Afghanistan. All participants gave blood samples for genetic and metabolic analyses and were evaluated for psychiatric conditions. They also underwent magnetic resonance imaging (MRI) to examine brain structure and function.

Spotlight

Crops and foods today are not what they used to look like. Farmers and plant breeders have been modifying plant genes since the earliest human communities were formed and farming took hold in order to develop crops that better resist pests and foods with improved nutrition and taste. Biotechnology proponents, particularly agro-biotechnology corporations, like to claim that humans have been genetically-modifying crops for thousands of years. Biotech advocates say that modern genetic techniques, including GMOs and CRISPR gene editing, are just a continuation of this time-tested process.  That’s true, sort of.  Modern corn, bananas, eggplant, Brussels sprouts.

Spotlight

Crops and foods today are not what they used to look like. Farmers and plant breeders have been modifying plant genes since the earliest human communities were formed and farming took hold in order to develop crops that better resist pests and foods with improved nutrition and taste. Biotechnology proponents, particularly agro-biotechnology corporations, like to claim that humans have been genetically-modifying crops for thousands of years. Biotech advocates say that modern genetic techniques, including GMOs and CRISPR gene editing, are just a continuation of this time-tested process.  That’s true, sort of.  Modern corn, bananas, eggplant, Brussels sprouts.

Related News

Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance

Business Wire | September 08, 2020

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the “BEAM Alliance”) as full member. The BEAM Alliance is a network of approximately 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (“AMR”), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents, and medical devices, including in-vitro diagnostics.

Read More

Sestina Bio Launches Engineering Biology to Create Revolutionary Products

Sestina Bio | October 17, 2020

Sestina Bio, a new company creating a platform for automated synthetic biology, today announced that it has launched with seed funding from Foresite Capital, General Inception and OMX Ventures. The funds will be used to further the development of its digital cellular engineering and phenotyping platforms and support initial product development. The firm is the first company to launch from incubator Foresite Labs. Practitioners of synthetic biology aim to engineer novel living organisms -- usually yeast and bacteria -- that produce new materials, fine and bulk chemicals, and pharmaceuticals, or which act as sensors that report on their environment. By combining new instruments for single cell genome editing, tools for single cell phenotyping, and closed-loop, machine learning-driven design and control of experiments, Sestina is developing the next generation of the automated synthetic biology toolkit. Sestina will harness these tools to rapidly and deterministically engineer new biological capabilities and produce novel products across several verticals.

Read More

CELL AND GENE THERAPY

Vizgen Releases Commercial MERSCOPE Platform

Vizgen | August 31, 2021

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number of commercial instruments for the next several months before releasing MERSCOPE to the U.S. market at large in late 2021. MERSCOPE is the first commercially available high-plex single-cell spatial genomics platform, and the only platform for MERFISH technology. Developed in the laboratory of Dr. Xiaowei Zhuang, a Howard Hughes Medical Institute Investigator, and David B. Arnold, Jr. Professor of Science at Harvard University, MERFISH provides the highest detection efficiency available for spatially profiling gene expression across whole tissues and resolving individual transcripts with nanometer-scale resolution through combinatorial labeling, sequential imaging, and error-robust barcoding. “This is a revolutionary time for the field of genomics. Researchers across the country are now able to access the spatial dimension to answer new kinds of scientific questions and make significant biological discoveries,” said Terry Lo, President and CEO of Vizgen. “Profiling the expression of hundreds of genes, in hundreds of thousands of cells, for hundreds of millions of transcripts all while retaining the spatial information within the tissue architecture has never been done before. What was previously unimaginable, MERSCOPE now makes routine.” About Vizgen Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company's MERSCOPETM platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development.

Read More